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Immunoscintigraphy using a monoclonal antibody is a technique
that makes it possible to get a specific image of a tumour
(Corbisiero et al, 1991; Collier et al, 1992; Gasparini et al, 1994).
However, delays caused by slow clearance of radioactivity from
normal organs prevent it from obtaining images soon after
the administration of radiolabelled reagent. Use of antibody frag-
ments (Fab) accelerates blood clearance of the radiolabel, but the
renal uptake of radiolabelled fragments is higher than that of intact
antibodies and the absolute amount accumulated in tumours is
relatively low.
Recently, we developed a new metabolizable linker, designated
HML, designed so that radioiodinated HML-protein conjugate
is metabolized and rapidly cleared from the body (Wakisaka
et al, 1997). The radioiodinated HML-protein conjugate is stable
in the serum but is rapidly metabolized in the liver to release
m-iodohippuric acid, which is cleared through the kidneys.
Vasoactive agents, such as angiotensin II, by producing vaso-
constriction in normal tissue, are known to divert arterial blood
selectively toward tumours and thereby enhance the delivery of
drug-loaded particles (Suzuki et al, 1981; Hori et al, 1985; Hori 
et al, 1993). Vasoactive agents have already been used clinically
to obtain high accumulations of systemically administered
chemotherapeutic drugs to malignant tumours, such as gastric
carcinoma (Sato et al, 1995). By combining the use of antibody
fragments radioiodinated with HML and angiotensin II treatment,
it may be possible to obtain high tumour uptake of radiolabelled
antibody with low background radioactivity sooner, which would
make it possible to obtain a clear image of the tumour soon after
administration of radiolabelled reagent. In the present study, we
investigated the effect of HML-radioiodination and angiotensin II
treatment on tumour uptake of radiolabelled antibody fragment
in tumour-bearing mice, and whether clear tumour images could
be obtained soon after administration of radiolabelled antibody
fragment.
MATERIALS AND METHODS
Experimental tumour
KT005 human osteosarcoma cells (Sakahara et al, 1987) were
grown in RPMI 1640 (Nissui, Tokyo, Japan) containing 10% fetal
calf serum (GI Laboratories, Grand Island, NY, USA) and 0.03%
L-glutamine at 37°C in 5% CO2. Subconfluent cells were removed
from the culture dishes using calcium- and magnesium-free phos-
phate-buffered saline (PBS) containing 0.02% EDTA to preserve
antigenicity, and 5 ´ 106 KT005 cells were inoculated subcuta-
neously into female Balb/c nu/nu mice. Tumours grew to approxi-
mately 800 mg 3 weeks after the inoculation. The tumours were
maintained by serial passage of subcutaneous tumour in the nude
mice.
Monoclonal antibodies and preparation of Fab
fragments
The OST7 antibody (IgG1 isotype) was raised using human
osteogenic sarcoma (Hosoi et al, 1982), and it has been shown to
react with human osteogenic sarcoma cells with an alkaline
phosphatase-related substance as an antigen (Tanaka et al, 1986;
Nakamura et al, 1987). OST7 antibody was purified from
the ascites of hybridoma-bearing mice using Protein A column
chromatography (Bio-Rad, Richmond, CA, USA). Monoclonal
antibody 56C (IgG1), which recognizes human chorionic
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gonadotropin, was used as the isotype-matched control antibody
(Kobayashi et al, 1993). Fab fragments were generated by papain
digestion of the whole IgG of OST7 and 56C. Papain was
added to IgG in 0.075 M phosphate buffered saline, pH 7.0, to
yield an enzyme–IgG weight ratio of 1:33. After incubation at
37°C for 1 h, the reaction was stopped by adding 10% volume of
0.5 M iodoacetamide. The Fab fragments were separated by
Superdex 200 column chromatography (Pharmacia Biotech,
Uppsala, Sweden) and were further purified from contaminated 
Fc fragments by Protein A affinity chromatography (Bio-Rad,
Richmond, CA, USA).
Radioiodination of Fab
Radioiodination of Fab fragments was done by a two-step proce-
dure (Arano et al, 1994; Wakisaka et al, 1997). First, HML was
radioiodinated, and the radioiodinated HML was then conjugated
to the Fab fragment. HML was dissolved in methanol containing
1% acetic acid (0.64 mg ml–1), and 32.6 ml of this solution was
mixed with 4 ml (14.8 MBq; 400 mCi) of Na[125I] (DuPont,
Wilmington, DE, USA). After addition of 8.88 ml of N-chloro-
succinimide (NCS) in methanol (0.5 mg ml–1), the reaction mixture
was incubated at room temperature for 25 min. Aqueous sodium
bisulphite (4.44 ml, 0.72 mg ml–1) was then added to quench the
reaction. The radiochemical yield of [125I]-HML was determined by
TLC developed with a mixture of chloroform–methanol–acetic
acid (40:5:2). Methanol was removed by an N2 flow prior to subse-
quent conjugation reaction with Fab.
Before conjugation with [125I]-HML, Fab was treated with
2-iminothiolan (IT), as previously reported (Arano et al, 1994).
Briefly, 14.4 ml of freshly prepared 2-IT (1.0 mg ml–1) in well-
degassed 0.1 M borate buffer (BB; pH 8.0) containing 2 mM
EDTA was added to 250 ml of Fab (2 mg ml–1) in the same buffer.
After gentle stirring at room temperature for 1 h, excess 2-IT was
removed by the centrifuged column procedure (Meares et al, 1984)
using a Sephadex G-50 gel (Pharmacia Biotech, Uppsala, Sweden)
equilibrated with well-degassed 0.1 M PB (pH 6.0) containing
2 mM EDTA. The filtrate solution (200 ml) was then added to the
reaction vial containing 12.6 MBq of crude [125I]-HML. After
gentle agitation of the reaction mixture for 1.5 h at room tempera-
ture, 29.6 ml of iodoacetamide (10 mg ml–1) in 0.1 M PB (pH 6.0)
was added into the mixture and incubated for 30 min. Then radio-
labelled Fab was purified by the centrifuged column procedure
using a Sephadex G-50 gel equilibrated with 0.1 M PB (pH 7.4).
The specific activities of the 125I-HML-IT-Fab (OST7) and 125I-
HML-IT-Fab (56C) were about 0.7 MBq mg–1 and 0.5 MBq mg–1,
respectively. Fab fragments were also radioiodinated by the
chloramine-T method (Hunter et al, 1962; Greenwood et al, 1963).
Purified Fab (50 mg) of OST7 in 0.3 M phosphate buffer (pH 7.5)
and  125I (11.1 MBq) were mixed with 2.5 mg of chloramine-T
(Nakarai Tesq, Kyoto, Japan) dissolved in 0.3 M phosphate buffer.
After reacting for 5 min, the radiolabelled Fab was separated from
free iodine by PD-10 gel chromatography (Pharmacia, Uppsala,
Sweden). The specific activity of the 125I-labelled-Fab was about
60.8 MBq mg–1.
Cell binding assay
The 125I-labelled-HML-IT-Fab (OST7), 125I-labelled-Fab (OST7)
and  125I-labelled-HML-IT-Fab (56C) (3–5 ng per 100 ml) were
incubated with increasing concentrations of KT005 cells (2 ´ 105–
5 ´ 106 per 100 ml) in 5.7 ´ 46 mm microcentrifuge tubes for 1 h
at 4°C. After centrifugation at 10 000 g, the supernatant was aspi-
rated and the tubes were cut. Then the radioactivity bound to the
cells was counted in an auto-well gamma counter. Specific
binding to the cells was calculated by subtracting the nonspecific
binding of 125I-labelled-HML-IT-Fab (56C) from the binding of
125I-labelled-HML-IT-Fab (OST7) and 125I-labelled-Fab (OST7).
The binding of 56C to OST7 was less than 3% of the added
radioactivity. The immunoreactive fraction of the radiolabelled
antibodies was determined by the method described by Lindmo
et al (1984).
Biodistribution studies
Biodistribution studies were performed when the tumours grew to
be about 200 mg in weight. Following a report by Kinuya et al
(1996a), micro-osmotic pumps (Altzet model 1003D, Alza, 
Palo Alto, CA, USA) filled with 1.2 mg ml–1 of [Asn–1,Val5]-
angiotensin II (Sigma, St. Louis, MO, USA) dissolved in saline
were implanted between scapulae of nude mice bearing KT005
xenografts, 4 h before the injection of radiolabelled HML-Fab.
Saline was filled in pumps for the control animals. The pumps
infused solution at a constant flow rate of 1.0 ml h–1 for 72 h under
physiological conditions at 37°C. At 1, 3 and 24 h after the admin-
istration of antibody, the mice were killed, and their organs were
removed, weighed and counted for radioactivity. The micro-
osmotic pumps were removed 1 h after the injection of the anti-
body. As a control study, a fragment of 56C antibody, and for
another group, Fab fragment of OST7 radioiodinated by chlor-
amine-T method, were injected with the angiotensin II treatment,
and biodistribution was studied at 3 h after the injection. The
experimental protocol is shown in Table 1. Data were expressed as
percentage of injected dose per gram of tissue, normalized to 20 g
mice, and also as tumour-to-normal tissue ratios.
Immunoscintigraphy
For the imaging of tumour-bearing nude mice, HML was radio-
iodinated with Na[131I], and subsequent conjugation with Fab frag-
ment of OST7 was performed by procedures similar to those used
for 125I-labelled-HML-IT-Fab (OST7). The specific activity of the
131I-labelled-HML-IT-Fab (OST7) was about 38.2 MBq mg–1. As
shown in Table 1, after treatment with angiotensin II, 7.7 MBq of
131I-labelled-HML-IT-Fab (OST7) was administered intravenously
via the tail vein. At 3 h after injection of radiolabelled Fab, mice
were anaesthetized by intraperitoneal injection of sodium pento-
barbital, and scintigrams were obtained using a gamma camera
equipped with a pinhole collimator (Hnatowich et al, 1987;
Sakahara et al, 1993).
Table 1 Experimental protocol
Time Activity
–4 h Administration of angiotensin II
or saline with micro-osmotic pump
0 h Radioiodinated Fab i.v.
1 h Removal of micro-osmotic pump
1 h, 3 h or 24 h Sacrifice and radioactivity count1796 Y Nakamoto et al
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Statistical analysis
Results were statistically analysed using unpaired t-test for in vivo
studies. Differences were considered significant when the P value
was less than 0.05.
All animal experiments were carried out in accordance with the
Japanese regulations regarding animal care and handling.
RESULTS
Cell binding assay
The HML method did not affect the immunoreactivity of OST7
fragment, and there was no significant difference in binding
to KT005 cells between 125I-labelled-HML-IT-Fab (OST7) and 125I-
labelled-Fab (OST7) (see Figure 1). The immunoreactive fractions
of the radiolabelled fragments were 67.5% and 61.7%, respectively.
Biodistribution studies
The biodistribution data of 125I-labelled-HML-IT-Fab (OST7, 56C)
and  125I-labelled-Fab (OST7) with or without angiotensin II
treatment are summarized in Table 2. In addition, Figure 2 shows
tumour-to-normal tissue ratios at 3 h after the injection of these
radiolabelled fragments. The percentage of injected dose per gram
of tissue (%ID g–1) of tumours at 1, 3 and 24 h with and without
angiotensin treatment after injection of 125I-labelled-HML-IT-Fab
(OST7) were 15.5% and 15.7%, 16.3% and 9.0%, and 3.4% and
3.1%, respectively, and a significant difference in tumour uptake
was observed between tumours with and without angiotensin treat-
ment at 3 h after the injection (P < 0.01). The %ID g–1 in blood and
kidneys at 3 h after the injection were 5.1% and 5.3%, 2.5% and
3.0%, respectively. The %ID g–1 in blood and kidneys at 3 h of 125I-
labelled-HML-IT-Fab (OST7) labelled by chloramine-T method
were 4.2% and 11.5%, respectively, the latter being significantly
higher than that of 125I-labelled-HML-IT-Fab (OST7). The non-
specific accumulation of control antibody 56C to the tumour was
low at 3 h. High tumour-to-normal tissue ratios ranging from
3.2 (blood) to 35.1 (muscle) were obtained using HML with
angiotensin treatment.
Immunoscintigraphy
The scintigraphic images were consistent with the results of
biodistribution data (Figure 3). A clear tumour image with low
background activity, including kidneys, was obtained as early as
3 h after injection of 131I-labelled-HML-IT-Fab (OST7).
DISCUSSION
Immunoscintigraphy and radioimmunotherapy using monoclonal
antibody have been used for the detection and treatment of malig-
nant tumours. However, delays caused by slow clearance of
unbound antibody from normal tissue and from blood is a problem
for both diagnostic and therapeutic applications. Multi-step
tumour targeting using a high-affinity binding system such as
(strept)avidin-biotin (1015 M–1) is an efficient method of over-
coming some of the problems in tumour targeting. In this
approach, a lower molecular weight ligand can be used as a carrier
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of radioisotope for the last step to give higher tumour-to-normal
organ ratios sooner, using the rapid clearance of unbound radio-
labelled ligand. Some encouraging results have been reported 
in experimental and clinical studies (Hnatowich et al, 1987;
Kalofonos et al, 1990; Paganelli et al, 1991; Saga et al, 1994;
Magnani et al, 1996). We also reported an avidin chase method to
facilitate the clearance of unbound radiolabelled biotinylated anti-
body from the circulation (Kobayashi et al, 1994; Yao et al, 1995).
However, these methods require multiple injections, which can be
troublesome. Moreover, they can cause the problem of creating a
human anti-streptavidin or anti-avidin antibody, as well as human
anti-mouse monoclonal antibodies.
Another approach to obtain high tumour-to-background ratios
soon after the injection of radiolabelled reagent is the use of frag-
ments, such as Fab and F(ab¢)2, or single-chain Fv (scFv) as a
carrier of radionuclide. Fab and F(ab¢)2 obtained by enzymatic
digestion of immunoglobulins demonstrate more rapid tumour
targeting, better penetration, and faster blood clearance than their
intact IgG molecules. Also, the absence of an Fc region and short
residence in the circulation contribute to lower immunogenicity of
antibody fragments in vivo. However, fragments have the disad-
vantage of high kidney uptake and lower absolute uptake in the
tumour than intact IgG (Yokota et al, 1993). Genetically engi-
neered scFv demonstrates much faster clearance from the circula-
tion than Fab and its tumour uptake is very low (Hu et al, 1996),
although dimer forms of scFv can increase absolute tumour
uptake. In the present study, we used Fab fragment that has an
intermediate character between IgG and scFv, obtained the results
of increased absolute uptake by angiotensin II treatment, and
decreased renal accumulation of radioactivity by a new conjuga-
tion technique. These methods could be used for scFv or other
antigen-binding small proteins as well as Fab fragments.
Figure 4 schematically illustrates the origin of tumour vascula-
ture from the preexisting vascular bed. Vessel segments are
ordered according to Strahler’s nomenclature (Strahler et al,
1957). Tumour neovasculature starts from the junction between
a3 and a2, and goes on to feed the growing tumour (Hori et al,
1990; Hori et al, 1993). Angiotensin II selectively increases the
a5
a4
a3 a3
a2
a2
c
Tumour
Figure 4 Schematic representation of the arrangement of arterioles and
tumour vessels. Arterioles were classified numerically according to Strahler’s
nomenclature: c, true capillaries; a2, terminal arterioles; a3–a5, arterioles;
arrows, direction of flow
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resistance of a2 vessels and induces hypertension. Since
angiotensin II does not affect the resistance of a3, tumour vascula-
ture originating from the terminal portion of a3 is not affected.
Angiotensin II treatment, therefore, selectively redistributes the
blood flow to the tumour vascular bed, and it has already been
used clinically for induced hypertension chemotherapy. This
method can also be applied in antibody-based tumour targeting,
and Kinuya et al (1996a) reported high tumour accumulation of
radiolabelled IgG in mice. We speculated that in induced hyperten-
sion, the increase in tumour accumulation would be higher using
Fab fragments than intact IgGs due to their smaller molecular size.
Indeed, in our study with Fab fragment, HML-Fab conjugate was
highly accumulated in the tumour.
HML is a new linker, which was designed to be metabolized in
the liver into the m-iodohippuric acid and excreted rapidly through
the kidneys. In vitro studies showed that HML-protein conjugates
were very stable in serum (Wakisaka et al, 1997). The binding
affinity of the 125I-labelled-HML-IT-Fab (125I-HML-Fab) to the
tumour cells was the same as 125I-labelled-Fab labelled by
chloramin-T method (125I-CT-Fab), but the in vivo studies showed
that, at 3 h after the injection of radioiodinated Fab with
angiotensin II pretreatment, %ID g–1 of tumour in 125I-HML-Fab
was significantly higher than that of 125I-CT-Fab, and %ID g–1 in
kidneys using 125I-HML-Fab was significantly lower than that
of 125I-CT-Fab, resulting in a markedly higher tumour-to-kidney
ratio using 125I-HML-Fab. The kidney uptake of 125I-CT-Fab
without angiotensin treatment at 1 h and 24 h were 69.03% and
0.42% (data not shown), respectively. The difference of the
radioactivity in the kidneys between 125I-CT-Fab and 125I-HML-
Fab resulted from clearance of radioiodine shortly after injection.
Consequently, the combination of angiotensin II pretreatment and
HML-radioiodination method made it possible to get high tumour
uptake with low background radioactivity including the kidney,
and also, this enables clear tumour imaging soon after injection of
radiolabelled Fab fragment.
Although the micro-osmotic pump filled with angiotensin was
removed at 1 h after injection of radioiodinated Fab, there was no
significant difference between the accumulation of tumour with
and without angiotensin treatment at 1 h, and it was not until 3 h
after the administration that we recognized the difference between
the groups with and without angiotensin treatment. Kinuya et al
reported that the increase of tumour blood flow and blood volume
were observed just 10 min after the administration of angiotensin
II by 201TI and 99mTc-HSA, and the effect of induced hypertension
was confirmed to disappear after the removal of the pump filled
with angiotensin II (Kinuya et al, 1996b; 1997). Therefore,
although the exact reason remains unknown, there might be some
secondary changes after induced hypertension by angiotensin II
that enhance tumour uptake of radiolabelled antibody even after
normalization of blood pressure. The uptake of 125I-HML-Fab to
the tumour (16.3%) was significantly higher than that of 125I-CT-
Fab (9.3%) (P < 0.01). A reason for this difference may be the
increased stability of 125I-HML-Fab, since 125I-CT-Fab seemed to
be dehalogenated at the tumour site, and free iodine accumulated
in the stomach. In addition, there was no statistically significant
difference between tumour accumulations of 125I-CT-Fab with and
without angiotensin treatment at 3 h. This may also be due to the
instability of 125I-CT-Fab compared to 125I-HML-Fab.
Positron emission tomography (PET) has several advantages
over conventional scintigraphy, including better spatial resolution
and accurate quantification of tissue uptake. Positron emitter
halogens, iodine-124 (124I) and fluorine-18 (18F) might be used for
radiolabelling of HML as well as iodine-131. Especially, 18F is a
widely used positron emitter. There have been some reports
describing monoclonal antibodies labelled with 18F (Garg et al,
1992; Vaidyanathan G et al, 1992). According to these reports,
tumour-to-normal tissue ratios were not high within a few hours of
administration. Therefore, a new conjugate of 18F-HML-Fab
would be more appropriate for PET imaging.
In conclusion, the combined use of a novel metabolizable linker,
HML, for radioiodination of Fab, and angiotensin II treatment,
demonstrated high accumulation of Fab in the tumour with low
background radioactivity, including the kidney, soon after the injec-
tion of radiolabel, resulting in successful tumour imaging, which
we named pharmacoimmunoscintigraphy. These results suggest
that PET scanning using 18F-labelled-HML-antibody fragment
conjugates would be feasible with this technique.
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